Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms

Current treatment results for relapsed/refractory acute myeloid leukaemia (AML) are typically poor.[1][1] Because some data suggest the value of increased anthracycline doses with intensive AML chemotherapies,[2][2],[3][3] we conducted a Phase I/II trial ([ClinicalTrials.gov][4]: [NCT02044796][5])